You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR BELINOSTAT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Belinostat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00274651 ↗ A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas Terminated Onxeo Phase 2 2006-01-01 Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.
NCT00301756 ↗ Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed National Cancer Institute (NCI) Phase 2 2006-09-01 This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant potential tumors. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00303953 ↗ PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 2006-01-01 This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
NCT00321594 ↗ Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed National Cancer Institute (NCI) Phase 1/Phase 2 2006-05-01 This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Belinostat

Condition Name

Condition Name for Belinostat
Intervention Trials
Peripheral T-cell Lymphoma 4
Lymphoma 4
Recurrent Adult Diffuse Large Cell Lymphoma 4
Anaplastic Large Cell Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Belinostat
Intervention Trials
Lymphoma 20
Lymphoma, T-Cell 13
Carcinoma 8
Leukemia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Belinostat

Trials by Country

Trials by Country for Belinostat
Location Trials
United States 174
Denmark 6
France 5
United Kingdom 5
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Belinostat
Location Trials
California 14
Florida 12
Texas 11
Maryland 11
New York 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Belinostat

Clinical Trial Phase

Clinical Trial Phase for Belinostat
Clinical Trial Phase Trials
Phase 3 3
Phase 2 17
Phase 1/Phase 2 8
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Belinostat
Clinical Trial Phase Trials
Completed 27
Recruiting 10
Terminated 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Belinostat

Sponsor Name

Sponsor Name for Belinostat
Sponsor Trials
National Cancer Institute (NCI) 24
Onxeo 11
Spectrum Pharmaceuticals, Inc 11
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Belinostat
Sponsor Trials
Industry 42
Other 33
NIH 25
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Belinostat: Clinical Trials, Market Analysis, and Projections

Introduction

Belinostat, marketed as Beleodaq, is a histone deacetylase (HDAC) inhibitor that has garnered significant attention for its therapeutic potential in various cancers, particularly in the treatment of peripheral T-cell lymphoma (PTCL). Here, we delve into the current status of clinical trials, market analysis, and future projections for belinostat.

Clinical Trials Update

Approved Indication: Peripheral T-Cell Lymphoma

Belinostat was approved by the U.S. Food and Drug Administration (FDA) on July 3, 2014, for the treatment of patients with relapsed or refractory PTCL. This approval was granted under the FDA’s accelerated approval program based on the drug's ability to induce complete and partial responses in clinical trials. A study involving 129 patients with relapsed or refractory PTCL showed an overall response rate of 25.8%, with 13 complete responses and 18 partial responses[1][4][5].

Ongoing and Planned Trials

  • Diffuse Large B-Cell Lymphoma: Belinostat is currently in Phase I clinical trials for the treatment of diffuse large B-cell lymphoma, a common type of non-Hodgkin lymphoma. The Phase I trials are assessing the safety and efficacy of belinostat in this setting, with a high phase transition success rate expected[2].
  • Other Indications: Belinostat has been or is being investigated for various other hematologic malignancies and solid tumors, including acute myeloid leukemia, B-cell lymphomas, advanced multiple myeloma, and several types of carcinomas. While some of these trials have shown promising results, others have had more mixed outcomes. For example, a Phase II study in acute myeloid leukemia did not show complete or partial responses, but stability of disease was observed in some patients[4].

Market Analysis

Current Market Position

Belinostat is one of the few approved treatments for relapsed or refractory PTCL, a rare and aggressive form of non-Hodgkin lymphoma. Its approval has filled a critical gap in the treatment landscape for this condition. The drug is marketed by Spectrum Pharmaceuticals, Inc., and has received orphan product designation due to its focus on a rare disease[5].

Market Growth and Projections

The HDAC inhibitor market, which includes belinostat, is anticipated to grow significantly over the coming years. According to DelveInsight, the HDAC inhibitor market is expected to see a substantial CAGR by 2034, driven by the development of novel HDAC inhibitors and their expanding therapeutic applications[3].

Competitive Landscape

Belinostat competes with other HDAC inhibitors such as pralatrexate (Folotyn) and romidepsin (Istodax), which are also approved for PTCL. However, belinostat's unique mechanism of action and its broad anti-neoplastic activity make it a valuable option in the treatment arsenal. The market is also seeing the emergence of new HDAC inhibitors like abexinostat, which is in advanced clinical trials for various cancers[3][4].

Safety and Efficacy

Safety Profile

Clinical trials have shown that belinostat has a manageable toxicity profile. The most common adverse events include anemia, thrombocytopenia, dyspnea, and neutropenia. Despite these side effects, the drug has been well-tolerated in most patients, allowing for continued treatment until disease progression or unacceptable toxicity[1][5].

Efficacy

The efficacy of belinostat in PTCL has been demonstrated through its ability to induce complete and partial responses. The median duration of response was 13.6 months, with some patients experiencing responses lasting over 36 months. This durability of response is a significant advantage in the treatment of relapsed or refractory PTCL[1].

Future Projections

Expanding Indications

Belinostat is being explored for its potential in treating other types of cancers beyond PTCL. The ongoing Phase I trial for diffuse large B-cell lymphoma and other investigations in various solid tumors and hematologic malignancies suggest a potential for broader therapeutic use[2][4].

Market Expansion

As the HDAC inhibitor market grows, belinostat is poised to benefit from increased awareness and adoption. The drug's approval in additional indications and its potential combination with other therapies could further enhance its market position.

Regulatory and Clinical Milestones

Continued approval for the current indication may be contingent upon the results of confirmatory trials. Positive outcomes from these trials and from ongoing studies in other cancer types will be crucial for the long-term success and expanded use of belinostat[4][5].

Key Takeaways

  • Approved for PTCL: Belinostat is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma.
  • Ongoing Trials: The drug is in Phase I trials for diffuse large B-cell lymphoma and is being investigated for other cancers.
  • Market Growth: The HDAC inhibitor market, including belinostat, is expected to grow significantly by 2034.
  • Safety and Efficacy: Belinostat has a manageable toxicity profile and has shown durable responses in PTCL.
  • Future Potential: The drug has potential for expanded indications and combination therapies.

FAQs

Q: What is belinostat used for?

A: Belinostat is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Q: What is the mechanism of action of belinostat?

A: Belinostat is a histone deacetylase (HDAC) inhibitor, which works by targeting specific enzymes to slow down the growth of cancer cells and promote their death.

Q: What are the common side effects of belinostat?

A: The most common side effects include anemia, thrombocytopenia, dyspnea, and neutropenia.

Q: Is belinostat approved for other types of cancer?

A: Currently, belinostat is approved only for PTCL, but it is being investigated for other types of cancers in ongoing clinical trials.

Q: What is the outlook for the HDAC inhibitor market?

A: The HDAC inhibitor market, including belinostat, is expected to see significant growth by 2034 due to the development of new drugs and expanding therapeutic applications.

Sources

  1. O'Connor, O. A., et al. "Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study." Journal of Clinical Oncology, vol. 33, no. 23, 2015, pp. 2492-2499.
  2. Pharmaceutical Technology. "Belinostat by Acrotech Biopharma for Diffuse Large B-Cell Lymphoma." Pharmaceutical Technology, 9 Sep. 2024.
  3. GlobeNewswire. "HDAC Inhibitor Market to Observe Stunning Growth During the Study Period 2020-2034 - DelveInsight." GlobeNewswire, 24 Apr. 2024.
  4. Aetna. "Belinostat (Beleodaq) - Medical Clinical Policy Bulletins." Aetna, 2024.
  5. ESMO. "FDA Approves Belinostat to Treat Patients with Peripheral T-cell Lymphoma." ESMO, 9 Jul. 2014.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.